ANI Pharmaceuticals

ANIP

Market cap $1.78B

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference as follows:

ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.

ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.

Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.

ANI Pharmaceuticals NASDAQ: ANIP reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease company,” led by growth in Cortrophin Gel and ILUVIEN, contributions from a new intellectual property licensing transaction with Harmony Biosciences, and steady generics performance.

ANIP, CMI and SDRL stand out in May as earnings acceleration stocks, with rising EPS growth trends signaling potential share price momentum.

ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript